Natural killer cell

INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference

Retrieved on: 
Monday, March 14, 2022
Research, GLOBE, TNF, U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Disease, Conference, Virginia BioTechnology Research Park, Senior, Security (finance), NASDAQ, Clinical trial, Company, Cancer, CEO, Oppenheimer, Inflammation, Biotechnology, Natural killer cell, Marketing, Pharmaceutical industry

Boca Raton, FL, March 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, announced today that RJ Tesi, MD., President and CEO has been invited to participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference.

Key Points: 
  • Boca Raton, FL, March 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patients immune system to fight disease, announced today that RJ Tesi, MD., President and CEO has been invited to participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference.
  • Dr Tesi will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference, which is being held virtually on March 15 17, 2022.
  • Dr. Tesi will participate in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group during the 2022 Maxim Group Virtual Growth Conference, which is being held virtually on March 28 30, 2022.
  • INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.

Nichi GLOW: Japanese Beta-Glucan, in Children With Autism Spectrum Disorder, Improves Behavior, Sleep, and Gut Microbiome in a Clinical Study

Retrieved on: 
Monday, March 14, 2022
Mental Health, Research, Seniors, Children, Clinical Trials, Biotechnology, Health, Consumer, Science, BMJ, Publication, GMP, Trial of the century, Autism, Aggregation, Gut–brain axis, Food, Neurodevelopmental disorder, GN, Research, Parent, Microglia, Neurodegeneration, Sleep, Aureobasidium pullulans, Multimedia, Neuron, Amyloid, Brain, CARS, Learning, Reading, Allergen, Natural killer cell, Solution, Disease, ASD, Autism spectrum, Vaccine, Dementia

Beneficial reconstitution of gut microbiota was also reported with Nichi GLOW, which is unique from other beta glucans by its source, production method, and purity.

Key Points: 
  • Beneficial reconstitution of gut microbiota was also reported with Nichi GLOW, which is unique from other beta glucans by its source, production method, and purity.
  • One of them demonstrated his reading, writing and mathematical skills in a follow-up consulting with Dr Raghavan, developmental pediatrician & neurologist.
  • (Graphic: Business Wire)
    Autism is a neurodevelopmental disorder affecting 1 in 44 children in the developed world, with multiple causes and varying severity of manifestation.
  • Nichi GLOW controlled enterobacteria, a gut microbiome producing harmful proteins like curli and amyloid, leading to Alpha-synuclein misfolding and aggregation in the neurons, a cause of the disease ( https://doi.org/10.1101/2021.10.26.21265505 ).

INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3

Retrieved on: 
Wednesday, February 23, 2022
PIN, Security (finance), Process control block, NASDAQ, Company, Clinical trial, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Cancer, TNF, Patient, Marketing, Inflammation, Research, Natural killer cell, Pharmaceutical industry

Boca Raton, Florida, Feb. 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Thursday, March 3, 2022 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2021 and to provide a corporate update.

Key Points: 
  • A replay will also be available through March 10 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no.
  • is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.
  • The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Global NK Cell Therapies 2022: Insights into 80+ Companies and 100+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, February 18, 2022
Research, Stem Cells, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Chronic lymphocytic leukemia, ADCC, Cancer, Head, IPH2201, CD8, Merkel-cell carcinoma, Natural killer cell, Myelodysplastic syndrome, Immune system, Acute myeloid leukemia, NK-92, Hepatocellular carcinoma, GMP, Perforin, Therapy, Immortalised cell line, Cell, Glioblastoma, Phase II, ALECSAT, Sanofi, Isatuximab, Breast cancer, Multiple myeloma, TILS, Mergers and acquisitions, Squamous cell carcinoma, Infection, Antibody, CD122, Disease, Karolinska University Hospital, Nature, CD16, Lymphatic system, NK, Natural killer T cell, Hank, ANK, Pharmaceutical industry, Vaccine, Phase

This report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in NK Cell therapy pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in NK Cell therapy pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence NK Cell therapy R&D.
  • The therapies under development are focused on novel approaches to treat/improve NK Cell therapy.
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of NK Cell therapy?

INmune Bio, Inc. to Present at the BIO CEO & Investor Conference

Retrieved on: 
Tuesday, February 8, 2022
NASDAQ, Private Securities Litigation Reform Act, Natural killer cell, BOCA, GLOBE, TNF, U.S. Securities and Exchange Commission, Process control block, Conference, Research, Company, Cancer, Marketing, Clinical trial, Washington Marriott Marquis, Patient, Security (finance), Marriott Marquis, CEO, Inflammation, BIO, Disease, MD, Pharmaceutical industry

Please contact your representative at BIO to schedule a virtual one-on-one meeting with INmune Bio during the respective conference.

Key Points: 
  • Please contact your representative at BIO to schedule a virtual one-on-one meeting with INmune Bio during the respective conference.
  • is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
  • INmune Bio has two product platforms that are both in clinical trials.
  • INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.

INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer

Retrieved on: 
Tuesday, January 25, 2022
U.S. Securities and Exchange Commission, Multiple myeloma, TME, Cytokine, Head, Security (finance), Squamous cell carcinoma, Process control block, Patient, UCL, Chinese University of Hong Kong, Dry ice, IL4, GLOBE, EBV, Neoplasm, TGF, Lymphoma, Inflammation, Ovarian cancer, Clinical trial, Private Securities Litigation Reform Act, TNF, IL15, Time, IL10, Toxic epidermal necrolysis, Leukemia, CUHK, Breast cancer, Cell, University College London, Cancer, Immune system, NK, Safety, Cytokine release syndrome, Research, Memory, IL12, Disease, Company, CIML, History, Protein, IL2, Marketing, Survival, NPC, Incidence, Epstein–Barr virus infection, IL18, NASDAQ, Mortality, Natural killer cell, Vaccine, Pharmaceutical industry

We are confident that these INKmune primed cells will kill NPC tumor cells very effectively and we look forward to a mutually beneficial collaboration.

Key Points: 
  • We are confident that these INKmune primed cells will kill NPC tumor cells very effectively and we look forward to a mutually beneficial collaboration.
  • History of EBV infection (commonly known as mono) and genetic polymorphisms drive the incidence of the disease, said RJ Tesi, INmune Bios Chief Executive Officer.
  • This peer-reviewed grant and international collaboration targeting what has historically been a difficult to treat solid tumor validates the versatility of INKmune.
  • Tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma, ovarian cancer, breast cancer.

Life Biosciences, Leading Developer of Therapeutics for Aging-Related Diseases, Completes $82 Million Series C Financing Round

Retrieved on: 
Wednesday, January 5, 2022
Natural killer cell, NASH, CMA, Chaperone-mediated autophagy, Nature, Therapy, Growth, Research, Cell, Obesity, Merrimack Pharmaceuticals, Science, Series, Protein, Neurodegeneration, Ageing, Senior, Medicine, Glaucoma, Alpha wave, Biology, Applied Genetic Technologies Corporation, Pharmaceutical industry

BOSTON, Jan. 5, 2022 /PRNewswire/ -- Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced the completion of a Series C financing of $82 million led by Alpha Wave Ventures.

Key Points: 
  • BOSTON, Jan. 5, 2022 /PRNewswire/ -- Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced the completion of a Series C financing of $82 million led by Alpha Wave Ventures.
  • Senior management and founders invested in the Series C financing alongside longevity-oriented funds, seasoned investors, and experienced biotechnology scientists/entrepreneurs.
  • Life Biosciences' experienced management team is committed to bringing potentially pioneering science to the service of humanity."
  • Proceeds from the Series C financing will be used to accelerate research and development activities in the company's three platforms that target fundamental biological mechanisms contributing to aging.

INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting

Retrieved on: 
Tuesday, January 4, 2022
Natural killer cell, Clinical trial, Edwards Lifesciences, Research, Company, Patient, Cancer, U.S. Securities and Exchange Commission, Security (finance), Private Securities Litigation Reform Act, Disease, Inflammation, Process control block, NASDAQ, Hospital, Marketing, GLOBE, TNF, Trade, Pharmaceutical industry

Details of the event are as follows:

Key Points: 
  • Details of the event are as follows:
    David Moss, Chief Financial Officer, will participate in a panel discussion at the LifeSci Advisors 11th Annual Corporate Access Event.
  • Please contact your representative at H.C. Wainwright to schedule a virtual one-on-one meeting.
  • INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer Symposium

Retrieved on: 
Thursday, December 9, 2021
U.S. Securities and Exchange Commission, Təsi, RJ, TNBC, Company, Research, GLOBE, Immunotherapy, Disease, Security (finance), MFS, Woman, PFS, Private Securities Litigation Reform Act, TNF, Breast cancer, Phenotype, Patient, Cancer, Process control block, Natural killer cell, HIV disease progression rates, Immunosuppression, Inflammation, MUC4, Clinical trial, Survival, TME, M.D, NASDAQ, Marketing, Tumor microenvironment, Poster, Instituto de Biología y Medicina Experimental, Pharmaceutical industry, Medical imaging, Birth control, Vaccine

Boca Raton, Florida, Dec. 09, 2021 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces data to be presented at the San Antonio Breast Cancer Symposium showing  mucin 4 (MUC4) expression predicts worse survival and is a treatment resistance factor in women with triple negative breast cancer (TNBC).  INB03, a DN-TNF therapy, can reverse TNBC treatment resistance by decreasing expression of MUC4 and reducing immunosuppression in the tumor microenvironment (TME) by increasing anti-tumor macrophage phagocytosis and increasing lymphocyte function in the TME.  The poster will be presented by Dr. Roxana Schillaci, Instituto de Biología y Medicina Experimental, Buenos Aires, on December 10th.

Key Points: 
  • The poster will be presented by Dr. Roxana Schillaci, Instituto de Biologa y Medicina Experimental, Buenos Aires, on December 10th.
  • Now, in both TNBC and HER2+ breast cancer, MUC4 predicts resistance to immunotherapy and an immunosuppressive TME that can be overcome with INB03.
  • Treatment with INB03 in murine models of breast cancer improves macrophage anti-tumor phagocytic activity, lymphocyte infiltration and function suggesting improved response to combination therapies of INB03 with inmunotherapy.
  • INmune Bios product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.

Retrieved on: 
Wednesday, December 1, 2021
Patient, Private Securities Litigation Reform Act, Security (finance), Ovarian cancer, Cell, ECOG, Disease, Inflammation, Company, Cancer, Clinical trial, Acute myeloid leukemia, Doctor of Philosophy, Natural killer cell, NK, U.S. Securities and Exchange Commission, Lymphoma, Breast cancer, ALL, Immortalised cell line, Cytokine, Family, Survival, Research, Society, Neoplasm, GLOBE, Marketing, Acute lymphoblastic leukemia, Leukemia, Cytomegalovirus, Process control block, Phenotype, ILC, CMV, NASDAQ, Myelodysplastic syndrome, TNF, Multiple myeloma, Pharmaceutical industry, Mobile phone, Vaccine, Medical imaging

These are the first comprehensive data showing that INKmune-mediated priming generates NK cells with memory-like phenotype (mlNK).

Key Points: 
  • These are the first comprehensive data showing that INKmune-mediated priming generates NK cells with memory-like phenotype (mlNK).
  • These in vitro data have been replicated in the first patient treated with three, weekly doses of INKmune for high risk MDS.
  • Details of the presentations are as follows:
    Natural killer (NK) cells are innate lymphocytes that target virus-infected and tumor cells.
  • Their unique phenotypic and gene expression signatures suggest a novel and distinct form of memory-like NK cell governed by tumor-specific signaling pathways.